Literature DB >> 10675573

Heparin and oral anticoagulants in the treatment of brain ischemia.

C J Chaves1, L R Caplan.   

Abstract

The use of heparin, heparin analogues, and oral anticoagulation in the treatment of brain ischemia remains controversial. We review the mechanism of action of the heparins and warfarin as well as the data regarding their efficacy and complications in patients with ischemic stroke and venous sinus thrombosis. None of these drugs have proven effective for all forms of cerebral ischemia. Further studies examining the efficacy of anticoagulants in different stroke subgroups will be necessary in order to clarify optimal clinical practice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675573     DOI: 10.1016/s0022-510x(99)00299-3

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  4 in total

1.  Predictive factors for acute thrombogenesis occurring immediately after bypass procedure for moyamoya disease.

Authors:  Takeshi Mikami; Hime Suzuki; Ryo Ukai; Katsuya Komatsu; Yukinori Akiyama; Masahiko Wanibuchi; Kiyohiro Houkin; Nobuhiro Mikuni
Journal:  Neurosurg Rev       Date:  2019-02-14       Impact factor: 3.042

2.  Relationship between thrombus attenuation and different stroke subtypes.

Authors:  J M Niesten; I C van der Schaaf; G J Biessels; A E van Otterloo; T van Seeters; A D Horsch; M J A Luitse; Y van der Graaf; L J Kappelle; W P T M Mali; B K Velthuis
Journal:  Neuroradiology       Date:  2013-06-21       Impact factor: 2.804

3.  Comparative evaluation of warfarin utilisation in two primary healthcare clinics in the Cape Town area.

Authors:  Xolani W Njovane; Pius S Fasinu; Bernd Rosenkranz
Journal:  Cardiovasc J Afr       Date:  2013-03       Impact factor: 1.167

4.  Histopathologic composition of cerebral thrombi of acute stroke patients is correlated with stroke subtype and thrombus attenuation.

Authors:  Joris M Niesten; Irene C van der Schaaf; Lievay van Dam; Aryan Vink; Jan Albert Vos; Wouter J Schonewille; Peter C de Bruin; Willem P T M Mali; Birgitta K Velthuis
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.